Maryam Sabour Takanlou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maryam Sabour Takanlou has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Leila Sabour Takanlou
Department of Medical Biology Faculty of Medicine Ege University Izmir Türkiye
6 shared publications - Cigir Biray Avci
Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
4 shared publications - Arman Rostamlou
Department of Medical Biology, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey
2 shared publications - Altuğ Yavaşoğlu
Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey
1 shared publication - Aylin Buhur
İstanbul Galata Üniversitesi Diş Hekimliği Fakültesi, Temel Bilimler, Beyoğlu, İstanbul, Türkiye
1 shared publication - Belguzar Karadag
Department of Biochemistry, Faculty of Science, Ege University, 35100 Izmir, Turkey; Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
1 shared publication
Latest Publications
- 6 May 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (9) , 1-26
Post-Transcriptional Knockdown of BRCC3 via siRNA-Loaded Niosomes Modulates Autophagy and Endoplasmic Reticulum Stress in Rotenone-Induced Parkinson’s Disease Model
Parkinson’s Disease (PD) is the second most common neurodegenerative ailment, manifesting with motor symptoms such as tremor, bradykinesia, muscular rigidity, and postural instability, resulting fr...
- 6 May 2026
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 34 (9) , 1-26
Post-Transcriptional Knockdown of BRCC3 via siRNA-Loaded Niosomes Modulates Autophagy and Endoplasmic Reticulum Stress in Rotenone-Induced Parkinson’s Disease Model
Parkinson’s Disease (PD) is the second most common neurodegenerative ailment, manifesting with motor symptoms such as tremor, bradykinesia, muscular rigidity, and postural instability, resulting fr...
- 4 March 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 457
BET inhibition enhances temozolomide sensitivity in cervical cancer cells through ALDH suppression and epigenetic reprogramming
Highlights JQ1 modulates temozolomide responsiveness and apoptotic signaling in HeLa cervical cancer cells. Combined JQ1 and TMZ treatment alters oxidative stress–related parameters associated with chemoresistance. JQ1 and TMZ co-treatment induces distinct transcriptional changes in chromatin-modifying enzymes. Epigenetic reprogramming involves coordinated alterations in acetylation- and methylation-related gene expression. Findings suggest BET inhibition as a potential strategy to enhance therapeutic responses in cervical cancer.
- 4 March 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 457
BET inhibition enhances temozolomide sensitivity in cervical cancer cells through ALDH suppression and epigenetic reprogramming
Highlights JQ1 modulates temozolomide responsiveness and apoptotic signaling in HeLa cervical cancer cells. Combined JQ1 and TMZ treatment alters oxidative stress–related parameters associated with chemoresistance. JQ1 and TMZ co-treatment induces distinct transcriptional changes in chromatin-modifying enzymes. Epigenetic reprogramming involves coordinated alterations in acetylation- and methylation-related gene expression. Findings suggest BET inhibition as a potential strategy to enhance therapeutic responses in cervical cancer.
- 10 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 270
The impact of the telomerase inhibitor on the Wnt signaling pathway in breast cancer and breast cancer stem cells
Background Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide. Breast cancer stem cells (BCSCs) contribute to tumor initiation, metastasis, recurrence, and resistance to therapy. The Wnt signaling pathway is a major regulator of stemness properties and is associated with poor clinical outcomes. BIBR1532 is a selective telomerase inhibitor widely used in cancer research due to its ability to inhibit telomerase activity in tumor cells with minimal toxicity in normal tissues. This study aimed to investigate the effects of BIBR1532 on the Wnt signaling pathway in breast cancer cells and BCSCs. Methods Cytotoxicity of BIBR1532 was evaluated in MCF-7 breast cancer cells, MCF10A normal breast epithelial cells, and BCSCs using a 48-hour treatment. IC₅₀ values were calculated, and apoptosis induction was assessed. Changes in the expression of Wnt pathway–related genes following BIBR1532 treatment were analyzed using RT-qPCR. Results The IC₅₀ values of BIBR1532 at 48 h were 35.29 µM for MCF-7, 28.16 µM for MCF10A, and 30.42 µM for the BCSC line. BIBR1532 markedly induced apoptosis in MCF-7 and BCSCs, whereas minimal apoptotic changes were observed in MCF10A cells. RT-qPCR analysis revealed significant modulation of genes in the Wnt signaling pathway: several oncogenic components were downregulated, while multiple tumor-suppressive genes were upregulated. Additionally, expression changes in less-studied Wnt-related genes may provide new insights for future breast cancer research. Conclusions BIBR1532 exerts selective cytotoxic and pro-apoptotic effects on breast cancer cells and BCSCs and modulates key components of the Wnt signaling pathway. These findings suggest that telomerase inhibition may influence stemness-related signaling in breast cancer.
- 10 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 270
The impact of the telomerase inhibitor on the Wnt signaling pathway in breast cancer and breast cancer stem cells
Background Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide. Breast cancer stem cells (BCSCs) contribute to tumor initiation, metastasis, recurrence, and resistance to therapy. The Wnt signaling pathway is a major regulator of stemness properties and is associated with poor clinical outcomes. BIBR1532 is a selective telomerase inhibitor widely used in cancer research due to its ability to inhibit telomerase activity in tumor cells with minimal toxicity in normal tissues. This study aimed to investigate the effects of BIBR1532 on the Wnt signaling pathway in breast cancer cells and BCSCs. Methods Cytotoxicity of BIBR1532 was evaluated in MCF-7 breast cancer cells, MCF10A normal breast epithelial cells, and BCSCs using a 48-hour treatment. IC₅₀ values were calculated, and apoptosis induction was assessed. Changes in the expression of Wnt pathway–related genes following BIBR1532 treatment were analyzed using RT-qPCR. Results The IC₅₀ values of BIBR1532 at 48 h were 35.29 µM for MCF-7, 28.16 µM for MCF10A, and 30.42 µM for the BCSC line. BIBR1532 markedly induced apoptosis in MCF-7 and BCSCs, whereas minimal apoptotic changes were observed in MCF10A cells. RT-qPCR analysis revealed significant modulation of genes in the Wnt signaling pathway: several oncogenic components were downregulated, while multiple tumor-suppressive genes were upregulated. Additionally, expression changes in less-studied Wnt-related genes may provide new insights for future breast cancer research. Conclusions BIBR1532 exerts selective cytotoxic and pro-apoptotic effects on breast cancer cells and BCSCs and modulates key components of the Wnt signaling pathway. These findings suggest that telomerase inhibition may influence stemness-related signaling in breast cancer.
- 7 February 2025
- Published by Elsevier in Bioelectrochemistry
- Vol. 164, 108937
Electrodeposition of carbon nanotubes and conjugation of arginyl-glycyl-aspartic acid for the following of glioblastoma cells on bionanocomposites
- 7 February 2025
- Published by Elsevier in Bioelectrochemistry
- Vol. 164, 108937
Electrodeposition of carbon nanotubes and conjugation of arginyl-glycyl-aspartic acid for the following of glioblastoma cells on bionanocomposites
- 19 March 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 124-135
Nilotinib Exerts a Therapeutic Approach via JAK/STAT Pathway and Cytokine Network in Chronic Myeloid Leukemia Cells
- 19 March 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 124-135
Nilotinib Exerts a Therapeutic Approach via JAK/STAT Pathway and Cytokine Network in Chronic Myeloid Leukemia Cells
- 10 September 2021
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (3) , 217-223
The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis
Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.
- 10 September 2021
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (3) , 217-223
The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis
Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.